EODData

MEMBERSHIP REGISTER LOG IN

NYSE, BMY:

03 Sep 2025
LAST:

47.50

CHANGE:
 0.09		OPEN:
47.32		HIGH:
48.51		ASK:
62.59		VOLUME:
8.38M
CHG(%):
0.19		PREV:
47.41		LOW:
47.30		BID:
62.58		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 2547.3248.5147.3047.508.38M
02 Sep 2547.3047.8647.0447.419.51M
29 Aug 2546.9947.3646.8247.1810.69M
28 Aug 2547.6347.6546.6546.887.87M
27 Aug 2547.3047.8447.1947.638.56M
26 Aug 2547.2047.4046.9947.2112.2M
25 Aug 2547.9748.1546.9447.1410.86M
22 Aug 2548.8449.1147.7247.9211.61M
21 Aug 2548.2648.9248.0748.438.78M
20 Aug 2548.5049.5848.2448.269.8M

COMPANY PROFILE

Name:
About:Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Sector:Healthcare
Address:Route 206 & Province Line Road, Princeton, NJ, United States, 08543
Website:https://www.bms.com
CUSIP:110122108
CIK:0000014272
ISIN:US1101221083
FIGI:BBG000DQLV23
LEI:HLYYNH7UQUORYSJQCN42

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:19.25
DivYield:0.05
Div/Share:2.46
Price to Book:5.59
Price to Sales:2.04
EBITDA:19.114B
Shares:2.035B
Market Cap:96.683B

TECHNICAL INDICATORS

MA5:47.32
MA10:47.56
MA20:47.24
MA50:47.06
MA100:47.62
MA200:52.73
STO9:27.80
STO14:22.96
RSI14:46.09
WPR14:-60.26
MTM14:-0.31
ROC14:-0.01
ATR:0.89
Week High:48.51
Week Low:46.65
Month High:49.58
Month Low:43.88
Year High:63.33
Year Low:42.96
Volatility:30.97

RECENT SPLITS

Date Ratio
07 Aug 20011000000-951777
01 Mar 19992-1
03 Mar 19972-1

RECENT DIVIDENDS

Date Amount
03 Jul 2025$0.62
04 Apr 2025$0.62
03 Jan 2025$0.62
04 Oct 2024$0.60
05 Jul 2024$0.60
04 Apr 2024$0.60
04 Jan 2024$0.60
05 Oct 2023$0.57
06 Jul 2023$0.57
06 Apr 2023$0.57